Randomized controlled open label trial on the use of favipiravir combined with inhaled interferon beta-1b in hospitalized patients with moderate to severe COVID-19 pneumonia

• Published in: International journal of infectious diseases Vol. 102; pp. 538 - 543
• Main Authors: Khamis, Faryal, Al Naabi, Hanan, Al Lawati, Adil, Ambusaidi, Zaiyana, Al Sharji, Mariam, Al Barwani, Umkulthum, Pandak, Nenad, Al Balushi, Zakariya, Al Bahrani, Maher, Al Salmi, Issa, Al-Zakwani, Ibrahim
• Format: Journal Article
• Language: English
• Published: Canada Elsevier Ltd 01.01.2021; The Authors. Published by Elsevier Ltd on behalf of International Society for Infectious Diseases; Elsevier
• Subjects: Administration, Oral; Adult; Aged; Amides - administration & dosage; Antiviral Agents - administration & dosage; COVID-19 - virology; COVID-19 Drug Treatment; Drug Therapy, Combination; Female; Hospitalization; Humans; Hydroxychloroquine - administration & dosage; Interferon beta-1b - administration & dosage; Male; Middle Aged; Pyrazines - administration & dosage; SARS-CoV-2 - drug effects; SARS-CoV-2 - physiology; Treatment Outcome

•Favipiravir and inhaled interferon compared with with hydroxychloroquine for moderate to severe COVID-19 pneumonia.•No difference between the 2 groups was found in time to recovary, inflammatory markers or improvement of oxygenation.•No differnece was found between the 2 groups in transfer to ICU o...